早期非小细胞肺癌的最佳放疗分割方案
研究基于56篇文献中9808例早期非小细胞肺癌患者的肿瘤控制概率(TCP)数据,验证HyTEC工作组开发的3个放射生物学模型,模型参数α/β约20 Gy能良好描述2-4 Gy/次常规放疗和立体定向体部放疗(SBRT)的TCP数据;TCP随生物有效剂量增加而急剧上升并达到渐近最大平台,从而确定1-30次分割的模型非依赖性最佳分割方案,T2肿瘤所需最佳剂量略高于T1肿瘤。
要点
- HyTEC模型(α/β约20 Gy)能良好描述早期非小细胞肺癌常规放疗和SBRT的TCP数据,数据来自56篇文献9808例患者。
- TCP与生物有效剂量间存在陡峭剂量反应,TCP达到渐近最大值,据此可确定1-30次分割的模型非依赖性最佳分割方案。
- T2肿瘤所需最佳剂量略高于T1肿瘤,所提出的最佳分割方案与早期非小细胞肺癌SBRT临床实践一致。
核心结论
- HyTEC放射生物学模型(α/β约20 Gy)能良好描述早期非小细胞肺癌2-4 Gy/次放疗和SBRT的近期TCP数据。
- TCP与生物有效剂量间存在陡峭剂量反应且达到渐近最大值,据此确定1-30次分割的模型非依赖性最佳分割方案。
- T2肿瘤所需最佳剂量略高于T1肿瘤,所提出的最佳分割方案与早期非小细胞肺癌SBRT临床实践一致。
研究设计与样本
- 本研究收集56篇已发表文献中9808例接受2-4 Gy/次放疗或SBRT的早期非小细胞肺癌患者的1、2、3、5年实际或Kaplan-Meier法TCP数据。
- 该数据集样本量接近原HyTEC样本的三倍,用于进一步验证根据临床TCP数据拟合确定的HyTEC模型参数。
主要发现
- 扩展数据集的TCP数据可被HyTEC模型良好描述,α/β比值约为20 Gy。
- TCP随生物有效剂量增加而急剧上升,并达到渐近最大平台。
关键数值与推荐
- HyTEC模型拟合得到的α/β比值约为20 Gy。
- 在原HyTEC样本基础上,采用9808例患者数据进一步验证模型参数。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: A series of radiobiological models were developed to study tumor control probability (TCP) for stereotactic body radiation therapy (SBRT) of early-stage non-small cell lung cancer (NSCLC) per the Hypofractionated Treatment Effects in the Clinic (HyTEC) working group. This study was conducted to further validate 3 representative models with the recent clinical TCP data ranging from conventional radiation therapy to SBRT of early-stage NSCLC and to determine systematic optimal fractionation regimens in 1 to 30 fractions for radiation therapy of early-stage NSCLC that were found to be model-independent. METHODS AND MATERIALS: Recent clinical 1-, 2-, 3-, and 5-year actuarial or Kaplan-Meier TCP data of 9808 patients from 56 published papers were collected for radiation therapy of 2 to 4 Gy per fraction and SBRT of early-stage NSCLC. This data set nearly triples the original HyTEC sample, which was used to further validate the HyTEC model parameters determined from a fit to the clinical TCP data. RESULTS: TCP data from the expanded data set are well described by the HyTEC models with α/β ratios of about 20 Gy. TCP increases sharply with biologically effective dose and reaches an asymptotic maximal plateau, which allows us to determine optimal fractionation schemes for radiation therapy of early-stage NSCLC. CONCLUSIONS: The HyTEC radiobiological models with α/β ratios of about 20 Gy determined from the fits to the clinical TCP data for SBRT of early-stage NSCLC describe the recent TCP data well for both radiation therapy of 2 to 4 Gy per fraction and SBRT dose and fractionation schemes of early-stage NSCLC. A steep dose response exists between TCP and biologically effective dose, and TCP reaches an asymptotic maximum. This feature results in model-independent optimal fractionation regimens determined whenever safe for SBRT and hypofractionated radiation therapy of early-stage NSCLC in 1 to 30 fractions to achieve asymptotic maximal tumor control, and T2 tumors require slightly higher optimal doses than T1 tumors. The proposed optimal fractionation schemes are consistent with clinical practice for SBRT of early-stage NSCLC.
引用
- Liu F, Ververs JD, Farris MK, et al. Optimal Radiation Therapy Fractionation Regimens for Early-Stage Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2023. PMID: 37734445. doi:10.1016/j.ijrobp.2023.09.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。